Outcomes of Utimpro Testing Implementation for Patients With Unexplained Recurrent Implantation Failure: A Single‐Center Retrospective Cohort Study
American Journal of Reproductive Immunology · 2025
DOI: 10.1111/aji.70131 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift American Journal of Reproductive Immunology, 2025. Verfasst von Genevieve Genest und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology and Allergy, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Embryo Implantation, Embryo Transfer, Endometrium, Infertility, Female. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Montreal General Hospital's.
Abstract (Originalsprache)
Problem A proportion of patients with unexplained recurrent implantation failure (uRIF) may have endometrial immune dysregulation amenable to treatment. Utimpro (Matrice lab Innove, Paris, France) is an endometrial immunophenotype test which identifies the absence or presence and type of immune dysregulation, proposing personalized protocol adjustments for a future embryo transfer (ET). Method of Study 2.5‐year single‐center retrospective cohort analysis of 121 patients who underwent Utimpro testing as a pilot study (January 2021—May 2023). Group 1 included 93 patients with uRIF, and Group 2 included 28 patients without RIF. Outcomes from Group 1 were compared to Group 3, a control cohort of 94 uRIF patients, outcomes for Group 2 were compared to Canadian average ongoing pregnancy rates (OPR) per ET. Primary outcome was pregnancy >32 weeks or live birth. Statistical analyses included the Student t ‐test or Mann–Whitney U test for continuous variables and the Fisher exact test for categorical data.
Results
In Group 1, 46/93 (49.5%) patients had a successful pregnancy compared to control (31/94 [33%], p = 0.026); when stratifying for RIF severity, patients with ≥ 5 failed blastocyst transfers benefitted most from Utimpro (21/38 [55.3%] vs. control 5/25 (20.0%), p = 0.0084). In Group 2, rates of OPR per ET with Utimpro recommendations did not differ from outcomes for non‐RIF patients (9/28 [32.1%]; 95% CI: 0.15–0.52 vs. 46.2%).
Conclusions
In patients with uRIF, our preliminary findings suggest that application of Utimpro recommendations was associated with a higher rate of successful outcomes; this was not the case for patients without RIF. These findings provide the rationale for an independent randomized controlled trial evaluating the large‐scale use of Utimpro in patients with uRIF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Immunology and Allergy, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, McGill University Health Centre, Montréal, Québec, Canada.
- The Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
- Division of Clinical Immunology and Allergy, Department of Medicine, Laval University, Québec, Canada.
- Department of Obstetrics and Gynecology, McGill University, McGill University Health Centre, Montréal, Québec, Canada.
- Department of Microbiology and Immunology, Faculty of Medicine and Health Sciences, McGill University, Montréal, QC, Canada.
Förderung
- Montreal General Hospital's
Zitieren
APA
Genest, G., Hochberg, A., Boivin, M., Ferreira, A., Liu, Z., Beauchamp, C., Beltempo, M., Dahan, M. H., Dahdouh, E. M., Demirtas, E., Hemmings, R., Jamal, W., Kadoch, I. J., Lapensée, L., Mahutte, N., Phillips, S., Reinblatt, S., Sylvestre, C., Buckett, W., …, & Piccirillo, C. A. (2025). Outcomes of Utimpro Testing Implementation for Patients With Unexplained Recurrent Implantation Failure: A Single‐Center Retrospective Cohort Study. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.70131
Vancouver
Genest G, Hochberg A, Boivin M, Ferreira A, Liu Z, Beauchamp C, et al. Outcomes of Utimpro Testing Implementation for Patients With Unexplained Recurrent Implantation Failure: A Single‐Center Retrospective Cohort Study. American Journal of Reproductive Immunology. 2025. doi:10.1111/aji.70131
BibTeX
@article{Genest2025,
author = {Genest, Genevieve and Hochberg, Alyssa and Boivin, Martine and Ferreira, Alexie and Liu, Zhiyang and Beauchamp, Coralie and Beltempo, Marc and Dahan, Michael H and Dahdouh, Elias M and Demirtas, Ezgi and Hemmings, Robert and Jamal, Wael and Kadoch, Isaac-Jacques and Lapensée, Louise and Mahutte, Neal and Phillips, Simon and Reinblatt, Shauna and Sylvestre, Camille and Buckett, William and Mazer, Bruce D and Piccirillo, Ciriaco A},
title = {Outcomes of Utimpro Testing Implementation for Patients With Unexplained Recurrent Implantation Failure: A Single‐Center Retrospective Cohort Study},
journal = {American Journal of Reproductive Immunology},
year = {2025},
doi = {10.1111/aji.70131}
}
EUVIMED